AUXOGYN

Auxogyn, a leader in women’s reproductive health, today announced the presentations of the latest data on its Eeva™ Test at the 30th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) 2014. The meeting will be held June 29^th through July 2^nd in Munich, Germany.

“I’m pleased our clinic partners have received this opportunity to share their clinical data on the Eeva Test with their peers from Europe and around the world this week at ESHRE,” said Lissa Goldenstein, CEO and President of Auxogyn. “The Eeva Test was clinically validated prior to its commercial availability and provides valuable information for embryo assessment to clinicians and patients. The research being presented at ESHRE this week shows potential for the Eeva Test that may expand its indications in the future.”

An abstract entitled “Computer-automated time-lapse analysis test results correlate to clinical pregnancy and embryo implantation: a prospective, blinded, multi-center study” was accepted as an oral presentation at ESHRE and presented earlier today by Dr. VerMilyea, the first author on the abstract.

“The clinical data from the interim analysis I presented at ESHRE on the Eeva System shows promise that the Eeva Test may have capabilities beyond blastocyst prediction,” said Matthew (Tex) VerMilyea, PhD, Scientific Director of Fertility Associates of New Zealand and previous Director of IVF & Andrology Laboratories, Penn Fertility Care at University of Pennsylvania that was a site for the study. “Our preliminary study results showed that Eeva Test results correlate positively with both implantation and pregnancy rates across multiple IVF clinics, although more clinical data is needed to substantiate these early results.”

Additional abstracts on the Eeva System technology accepted as poster presentations are as follows:

Automated time-lapse analysis in adjunctive use with morphology is highly informative in allowing diverse embryologists to select embryos with high developmental potential. Diamond, M. P.; Tan, L.; Conaghan, J.; Ivani, K.; Le, A; Chen, A.A.; Shen, S.; Suraj, V. Poster No. 115

Embryo assessment and selection by time-lapse evaluation using EEVA with transfer at the cleavage stage achieves similar clinical outcomes to blastocyst transfer. Gaudoin, M.; Adam, C.; Gibson, N.; Noble, C.; Mitchell, P.; Fleming, R. Poster No. 089

Categorisation of embryo developmental potential using computerised time-lapse evaluation of early stage development reveals differences in morphology and viability between three defined categories. Adam, C.; Gibson, N.; Noble, C.; Gaudoin, M.; Mitchell, P.; Fleming, R. Poster No. 136

“Auxogyn is committed to advancing reproductive medicine through scientific and clinical rigor, as evidenced though its support of these ongoing research studies, as well as our recent FDA clearance of the Eeva System as a first-of-its-kind device,” stated Goldenstein. “We’re dedicated to improving IVF outcomes and will continue to work with our clinics to assist in advancing the field.”

In addition to receiving FDA clearance in June 2014, the Eeva System is CE Marked and has been commercially available in the European Union since 2012 and Canada since 2013. Following the exclusive commercial licensing agreement in April 2014 the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, will offer the Eeva test to IVF clinics in Europe and Canada. It has already started to make the test available in selected countries. The division is a leader in fertility treatment committed to developing innovative science, medicines and technologies that have the power to improve outcomes for infertile couples throughout the IVF process.

Auxogyn plans to commercialize the Eeva Test in the United States later this year.

Full session details and data presentation listings for the 2014 meeting can be found on the ESHRE website at www.eshre.eu .

Auxogyn is exhibiting in the exhibit hall at ESHRE, booth No. B118.

About Auxogyn

Auxogyn is a leader in reproductive health that provides novel scientific and clinically validated solutions to IVF clinicians and their patients by translating scientific discoveries in early embryo development into clinical tools that improve patient outcome. The company’s flagship product, the Eeva Test, delivers objective information regarding embryo development that IVF clinicians and patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information, visit auxogyn.com  and follow the company on Twitter @Auxogyn .

About the Eeva System

Auxogyn’s Eeva System is the first and only non-invasive device FDA has cleared to date to aid in embryo selection. The Eeva Test is scientifically derived and clinically validated to identify embryos with the greatest development potential when used adjunctively to traditional morphology in women with multiple embryos deemed appropriate for transfer or freezing. Utilizing proprietary software and sophisticated computer vision technology, the Eeva Test automatically analyzes embryo development against scientifically and clinically validated cell-division timing parameters. With Eeva’s quantitative data on each embryo’s potential development, IVF clinicians can optimize the treatment path for their patients undergoing IVF procedures. Auxogyn received FDA clearance for the Eeva System in June, 2014. The Eeva System also received the CE mark in July 2012, and it is currently available for use in selected countries in the EU and Canada.

For more information regarding the Eeva Test, please visit www.eevaivf.com

Contact:

Auxogyn
Sherree Lucas, 650-681-0932
Vice President, Marketing
slucas@auxogyn.com

Link:

ClickThru